Symbol Lookup

Saturday July 26, 2014 1:11 PM ET. Data delayed 15 minutes.
13.67
0.26 (1.94%)
Bid/Lots
13.51/4
Ask/Lots
13.76/1
Open/Prev Close
13.28/13.41
Day Range
13.25-13.96
52-Week Range
10.40-23.25
Vol/Avg Daily Vol
34.0K/62.8K

TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

CARA Headlines

Go
Cara Therapeutics Earns Milestone Payment From Maruishi Pharmaceutical for Completion of Phase 1 Clinical Trial of I.V. CR845 in Japan
8:23AM ET on Wednesday Jul 16, 2014 by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that it has earned a $500,000 milestone payment from Maruishi Pharmaceutical Company, Ltd., for the completion of Maruishi's Phase 1 clinical trial of the I.V. formulation of Cara's novel kappa opioid agonist, CR845, in Japan.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that it has earned a ...

Peers Headlines

Jul 24, 2014

Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call
8:00AM ET on Thursday Jul 24, 2014 by PR Newswire
Companies Mentioned: XNCR

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release second quarte...

Jul 22, 2014

Cempra, Inc. to Report Second Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on July 29, 2014
4:11PM ET on Tuesday Jul 22, 2014 by GlobeNewswire
Companies Mentioned: CEMP

Cempra, Inc. (Nasdaq:CEMP) today announced that it will report second quarter 2014 financial results and provide a business update after the close of U.S. financial markets on July 29, 2014. Prabhavathi Fernandes, Ph.D., president and chief exe...

Jul 16, 2014

Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
8:35AM ET on Wednesday Jul 16, 2014 by PR Newswire
Companies Mentioned: RIGL

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). The focus of these clinical studies is to ...

Rigel Pharmaceuticals Initiates Phase 3 Clinical Trial of Blood Disease Treatment
7:43AM ET on Wednesday Jul 16, 2014 by Midnight Trader
Companies Mentioned: RIGL
07:43 AM EDT, 07/16/2014 (MT Newswires) -- Rigel Pharmaceuticals, Inc. (RIGL), a clinical stage drug company, said it has initiated a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP. The focus of these cli...
Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
7:30AM ET on Wednesday Jul 16, 2014 by PR Newswire
Companies Mentioned: RIGL

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). The focus of these clinical studies is to ...

Jul 15, 2014

Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer
8:00AM ET on Tuesday Jul 15, 2014 by PR Newswire
Companies Mentioned: XNCR

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Kurt Gust...